ANDA 72332, held by Purepac Pharm. Clorazepate Dipotassium.
As of Nov 15, 2026, ANDA 72332 (Clorazepate Dipotassium), held by Purepac Pharm, was not approved, with 0 approved supplements and 0 published complete response letters.
| Product | Active ingredient | Marketing |
|---|---|---|
| Clorazepate Dipotassium15MG ยท tablet;oral | Clorazepate Dipotassium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
